<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6482">
  <stage>Registered</stage>
  <submitdate>1/02/2017</submitdate>
  <approvaldate>1/02/2017</approvaldate>
  <nctid>NCT03042273</nctid>
  <trial_identification>
    <studytitle>High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection</studytitle>
    <scientifictitle>A Randomised, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of High Strength Cranberry (Pacran®) in Women With Recurrent Urinary Tract Infections (Cystitis)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PAC-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Urinary Tract Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - High Strength Cranberry
Other interventions - Placebo

Experimental: High Strength Cranberry - 1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months

Placebo Comparator: Placebo - 1 capsule of Matching Placebo orally daily for 6 months


Other interventions: High Strength Cranberry
Softgel capsule

Other interventions: Placebo
Soy oil to match High Strength Cranberry Softgel Capsule

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of UTI - cultured confirmed UTIs at a level of &gt;108cfu/L (105cfu/mL)</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Females aged 18-65 years, inclusive

          2. A history of recurrent urinary tract infection defined as =3 UTIs in the last year OR
             at least 2 UTIs occurring in the last 6 months. Each infection requires confirmation
             by a health professional and at least one infection confirmed by culture.

          3. Willing to answer questionnaires and comply with the study requirements

          4. Ability to swallow capsules

          5. Provided Written Informed Consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Microbial growth on urine culture of =107 cfu/L (104cfu/mL) within 7 days of Day 1

          2. A history of &gt;5 UTIs in the last 6 months (confirmed by self-report or health
             professional)

          3. Use of antibiotics or antibiotics for prophylaxis within 28 days of Day 1

          4. Use of any antibacterial products, that in the opinion of the Medical Investigator may
             interfere with the study outcomes, within 28 days of Day 1

          5. Regular use of Vaccinium containing products (e.g. all forms of blueberries,
             cranberries, bilberry, lingonberry , etc i.e fruit, dried fruit, pills, juices or
             supplements) within 28 days of Day 1 at the discretion of the Medical Investigator

          6. Presence of an intermittent or indwelling urinary catheter

          7. Anatomical abnormalities of the urinary tract</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>15/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>CSIRO Nutrition and Health Research Clinic - Adelaide</hospital>
    <postcode> - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Swisse Wellness Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Commonwealth Scientific and Industrial Research Organisation, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This clinical trial is a Phase 2, multicenter, placebo-controlled, double-blind, parallel-arm
      study to evaluate the efficacy and safety of High Strength Cranberry (500mg Pacran®) in
      preventing UTI (cystitis) in women with a history of recurrent UTI (rUTI).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03042273</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Welma Stonehouse, PhD</name>
      <address>CSIRO</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Bianca Benassi, PhD</name>
      <address />
      <phone>+61 8 8303 8982</phone>
      <fax />
      <email>Bianca.Benassi@csiro.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>